IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10584351 B1

PDFFull Text
Date of Patent:
Mar. 10, 2020

Filed:

Jul. 13, 2017

Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof

Applicant:

Intrexon Corporation, Blacksburg, VA (US);

Inventors:

Jeremiah F. Roeth, Blacksburg, VA (US);

Charles C. Reed, Souderton, PA (US);

Brandon Cuthbertson, Newland, CT (US);

Sunil Chada, Missouri City, TX (US);

William E. Fogler, Rockville, MD (US);

Assignee:

Intrexon Corporation, Blacksburg, VA (US);

Attorney:

Sterne, Kessler, Goldstein and Fox P.L.L.C.

Primary Examiner:

Maria Marvich

Int. Cl.
CPC ...
C12N 15/861 (2006.01); C07K 14/55 (2006.01); A61K 38/20 (2006.01); C07K 14/47 (2006.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01); C07K 14/54 (2006.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); A61K 38/44 (2006.01); A61K 48/00 (2006.01); C12N 5/0784 (2010.01);
U.S. Cl.
CPC ...
C12N 15/85 (2013.01); A61K 38/191 (2013.01); A61K 38/208 (2013.01); A61K 38/212 (2013.01); A61K 38/44 (2013.01); A61K 48/0066 (2013.01); C07K 14/5434 (2013.01); C12N 5/0639 (2013.01); C12N 15/86 (2013.01); C12N 15/861 (2013.01); C12N 2710/10343 (2013.01); C12N 2830/002 (2013.01); C12N 2840/203 (2013.01);
Abstract

This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.

Find Patent Forward Citations

Loading…